Foa R - Search Results

1

Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.

Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Liao XS, Cesano A, Matera L, Gillio Tos A, Tola E, et al. Foa R, et al. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:153-5. Bone Marrow Transplant. 1989. PMID: 2653494 Review.

2

Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells.

Lista P, Fierro MT, Liao XS, Bonferroni M, Brizzi MF, Porcu P, Pegoraro L, Foa R. Lista P, et al. Among authors: foa r. Eur J Haematol. 1989 May;42(5):425-30. doi: 10.1111/j.1600-0609.1989.tb01465.x. Eur J Haematol. 1989. PMID: 2786477

3

Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia.

Foa R, Giovarelli M, Fierro MT, Bonferroni M, Forni G. Foa R, et al. Nouv Rev Fr Hematol (1978). 1988;30(5-6):339-41. Nouv Rev Fr Hematol (1978). 1988. PMID: 3065732 Review.

4

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.

Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R. Fierro MT, et al. Among authors: foa r. Leukemia. 1988 Jan;2(1):50-4. Leukemia. 1988. PMID: 3257539

5

In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.

Lauria F, Raspadori D, Rondelli D, Ventura MA, Foà R. Lauria F, et al. Among authors: foa r. Leukemia. 1994 May;8(5):724-8. Leukemia. 1994. PMID: 8182932

6

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alphadagger.

Bellone G, Fierro MT, Liao XS, Tos AG, Bonferroni M, Pegoraro L, Foa R. Bellone G, et al. Among authors: foa r. Leuk Lymphoma. 1990;1(5-6):341-52. doi: 10.1080/10428199009169604. Leuk Lymphoma. 1990. PMID: 20394563

7

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.

Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F. Foa R, et al. Blood. 1991 Aug 15;78(4):1041-6. Blood. 1991. PMID: 1868239 Free article.

8

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.

Foa R, Guarini A, Gillio Tos A, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. Foa R, et al. Cancer Res. 1991 Feb 1;51(3):964-8. Cancer Res. 1991. PMID: 1988139

9

Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Guarini A, Cardona S, Gillio Tos A, Gavosto F, Mandelli F. Foa R, et al. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:98-102. Bone Marrow Transplant. 1990. PMID: 2202476 Clinical Trial. No abstract available.

10

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.

Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Guarini A, Tos AG, di Celle PF, Cesano A, Matera L. Foa R, et al. Blood. 1990 Oct 1;76(7):1349-54. Blood. 1990. PMID: 2207312 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

939 results

Search Page

Filters